Navigation Links
Bristol-Myers Squibb Finalizes Settlement of Previously Disclosed Federal Investigation into Pricing, Sales and Marketing Practices
Date:9/28/2007

NEW YORK, Sept. 28 /PRNewswire-FirstCall/ -- Bristol-Myers Squibb Company (NYSE: BMY) announced today that it has finalized a civil settlement agreement with the United States Department of Justice ("DOJ") and the Office of the United States Attorney for the District of Massachusetts resolving the previously disclosed investigations that began several years ago involving the company's drug pricing, and sales and marketing activities. The company announced in December 2006 that an agreement in principle had been reached. In connection with the settlement, the company has entered into a five-year corporate integrity agreement with the Office of the Inspector General of the Department of Health and Human Services ("OIG") that provides for, among other obligations, the continued development and maintenance of the company's compliance programs relating to the company's U.S. pharmaceuticals business.

As previously announced, the agreement provides for a civil resolution and payment of $499 million, the full amount of which has been reserved. There are no criminal charges against the company. The agreement will not affect the company's ongoing business with any customers, including the government.

Bristol-Myers Squibb is pleased to have resolved these matters from the past and is proud of its commitment to conduct business with the highest standards of integrity in its mission to extend and enhance human life.

Bristol-Myers Squibb is a global pharmaceutical and related health care products company whose mission is to extend and enhance human life.


'/>"/>
SOURCE Bristol-Myers Squibb Company
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1

Related medicine news :

1. A Settlement Over Stem Cell Controversy Through Scientific Research
2. Is Workers’ Comp. Settlements for Back Pain Fair
3. Solutions Possible for Providing Water and Sanitation in Poor Urban Settlements, Says WaterAid
4. Mills Rejects Maccas 20m Divorce Settlement Offer
5. Obesity Surgery Complication Rates Higher than Previously Thought
6. Child-Proof: Brain Mapping Safer for Children than Previously Thought
7. Nonfatal School Bus-Related Injuries To Children More Common Than Previously Thought
8. Arthritis drugs safer than previously declared
9. Liver Regeneration may Be Simpler Than Previously Thought
10. AIDS Incidence in India Far Lower Than Previously Estimated New Study
11. Velcade(R) Plus Doxil(R) Improves Previously Treated Multiple Myeloma Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2008)...y 21 /PRNewswire-FirstCall/ -- Aflac Incorporated,...presentation at the Sanford,C. Bernstein & Co., LL...nce,2008., President and Chief Financial Officer ...ted, and he is scheduled to make a presentation on...orated presentation, Mr.,Cloninger will discuss th...
(Date:5/21/2008)...d SILVER SPRING, Md., May 21 /PRNewswire-USNewswir... (ADAA),( http://www.adaa.org ) and The HealthCent... announced that ADAA will join,HealthCentral,s gro...and,health experts dedicated to helping people suf... advice and support they need to cope with the,con...
(Date:5/21/2008)...s 1st quarter profit, enhanced operations and new ...ELES, May 21 /PRNewswire-FirstCall/ -- InstaCare C...butor of at-home testing diagnostics,for the chron...eveloper of,patent-pending technologies for e-heal...s for the first quarter period-ended March 31, 200...
(Date:5/21/2008)... Adverse Events in TORCH Showed Frequency Highest ...ONTO and RESEARCH TRIANGLE PARK, N.C., May 21 /PRN...500/50 (fluticasone propionate and,salmeterol inha...er of,cardiovascular adverse events compared to ot...from the TOwards a Revolution in COPD Health,(TORC...
Breaking Medicine News(10 mins):Health News:Aflac Incorporated to Present at the Sanford C. Bernstein & Co., LLC Twenty-Fourth Annual Strategic Decisions Conference 2008 2Health News:The Anxiety Disorders Association of America and The HealthCentral Network Form Alliance to Develop New Online Resources for Anxiety Disorders 2Health News:The Anxiety Disorders Association of America and The HealthCentral Network Form Alliance to Develop New Online Resources for Anxiety Disorders 3Health News:InstaCare Corp. in Turnaround Reports 258% Revenues Increase in 1Q 2008 2Health News:InstaCare Corp. in Turnaround Reports 258% Revenues Increase in 1Q 2008 3Health News:InstaCare Corp. in Turnaround Reports 258% Revenues Increase in 1Q 2008 4Health News:InstaCare Corp. in Turnaround Reports 258% Revenues Increase in 1Q 2008 5Health News:Three-Year COPD Study Found No Increase in Cardiac Events With Advair(R) 500/50 2Health News:Three-Year COPD Study Found No Increase in Cardiac Events With Advair(R) 500/50 3
...lls, and AIDS/HIV is also one of them. It is obser...ed till the secondary levels show a// tendency to ...jumping at the first opportunity. The educated lot...rotected sex, according to a novel report on HIV. ...
...en on weight loss programmes, aspiring to melt awa...lulite is extremely obstinate// and never really g...New research has indicated that when women knock o...te actually makes the skin look worse. Cellulite h...
... share many characteristics with normal stem cells...oting tumor blood vessel// formation, and may hold...rch team reported in the August 15th issue of Canc..., associate professor at the Preston Robert Tisch ...
... University published his findings on a better sub..., this month//. According to peer-reviewed researc...it the kind of immune response doctors were lookin...esting, the vaccine was given to 100 volunteers at...
Other Medicine News:Health News:Cancer Stem Cells Could Hold Key to Brain Tumor Therapy 2
(Date:5/21/2008)... products highlight Watson,s commitment to urology...T, ORLANDO, Fla., May 21 /...ading specialty pharmaceutical company, announced,...n two Phase 3 products at,the American Urological ...e,a cardiac safety trial involving silodosin, an i...
(Date:5/21/2008)...N.J., May 21 /- Genta,Incor...multiple abstracts,featuring its lead oncology pro...of the American Society of Clinical Oncology (ASCO...acts include the following:, -- Initial Phase 1 ...an oral gallium-containing Compound. Poster #...
(Date:5/21/2008)...t American Urological Association Annual Meeting -...irstCall/ -- Researchers,from Dendreon Corporation...,demonstrating the potential of D-3263, Dendreon,s... Trp-p8 (a transmembrane cation channel protein al...erplasia (BPH)., The abstract (#2041), "Preclinic...
(Date:5/20/2008)...echnologies received positive results of nine mont...and Supralimus. The results unveiled during ..., India, May 20 /- Sahajanand Medical...ng developer and manufacturer of,drug-eluting sten...ve,randomized nine months results of PAINT trial ...
Breaking Medicine Technology:Watson Announces Positive Data for Its New Investigational Products for Benign Prostatic Hyperplasia and Overactive Bladder 2Watson Announces Positive Data for Its New Investigational Products for Benign Prostatic Hyperplasia and Overactive Bladder 3Watson Announces Positive Data for Its New Investigational Products for Benign Prostatic Hyperplasia and Overactive Bladder 4Watson Announces Positive Data for Its New Investigational Products for Benign Prostatic Hyperplasia and Overactive Bladder 5Watson Announces Positive Data for Its New Investigational Products for Benign Prostatic Hyperplasia and Overactive Bladder 6Genta Clinical Programs Featured in Multiple Abstracts at the Annual Meeting of the American Society of Clinical Oncology 2Genta Clinical Programs Featured in Multiple Abstracts at the Annual Meeting of the American Society of Clinical Oncology 3Dendreon Presents Preclinical Data Demonstrating Activity of Trp-p8 agonist, D-3263, in Benign Prostatic Hyperplasia 2Dendreon Presents Preclinical Data Demonstrating Activity of Trp-p8 agonist, D-3263, in Benign Prostatic Hyperplasia 3Dendreon Presents Preclinical Data Demonstrating Activity of Trp-p8 agonist, D-3263, in Benign Prostatic Hyperplasia 4Sahajanand Medical Technologies PAINT Trial Results Support Safety and Efficacy of the Infinnium and Supralimus Stents 2Sahajanand Medical Technologies PAINT Trial Results Support Safety and Efficacy of the Infinnium and Supralimus Stents 3Full Year 2007 Results Date Notification 21 February 2008 3232 1Full Year 2007 Results Date Notification 21 February 2008 3232 2Surgery improves quality of life for children with sleep apnea 11679 1Surgery improves quality of life for children with sleep apnea 11679 2Surgery improves quality of life for children with sleep apnea 11679 3Old dogs 3A Prior knowledge affects how consumers accept new information 11676 1Old dogs 3A Prior knowledge affects how consumers accept new information 11676 2National Lt Governors Association Endorses HERO Campaign 3B 1st National Association of State Elected Officials Supporting Grassroots Designated Driv 11673 1National Lt Governors Association Endorses HERO Campaign 3B 1st National Association of State Elected Officials Supporting Grassroots Designated Driv 11673 2
... results report no new stent thrombosis after two ...s., and BARCELONA, Spain, May 22, 2007,/PRNewswire...,announced four-year follow-up data from its TAXUS... safety and efficacy benefits,associated with a mo...(TM) paclitaxel-eluting stent system -- which is n...
...LONA, Spain--(BUSINESS WIRE)--May 22, 2007 - Profe...lbourne, Australia, on,Tuesday presented positive ...nical trial at the EuroPCR meeting in Barcelona, S...rdiac events and no,protocol-defined stent thrombo...avor(R) Resolute drug-eluting stent system with ne...
Other Medicine Technology:Taxus VI Clinical Trial Demonstrates Positive Long-Term Outcomes,for Moderate-Release Paclitaxel-Eluting Stent at Four Years 2Taxus VI Clinical Trial Demonstrates Positive Long-Term Outcomes,for Moderate-Release Paclitaxel-Eluting Stent at Four Years 3Medtronic Announces Positive Nine-Month Results for Endeavor,Resolute Next Generation Drug-Eluting Stent at EuroPCR 2Medtronic Announces Positive Nine-Month Results for Endeavor,Resolute Next Generation Drug-Eluting Stent at EuroPCR 3
Cushing bayonet forceps. Insulated.
Scleral blades designed for trabeculectomy and groove type incisions, scleral standard USA size.
Accurately tests for Nystagmus when rotated at 8-10 rpm. Drums are 10" high by 8" diameter. Light weight drum of professional quality with ball bearings for effortless spin mechanism. For use 24 to 3
Diagnose dry eye, assess the effectiveness of permanent punctal occlusion, collagen - dissolvable in 3-5 days, all are 2 mm long. Sterile
Medicine Products: